Pharmacyclics gets boost on 3rd ibrutinib 'breakthrough' designation, new data
This article was originally published in Scrip
Executive Summary
Shares of Pharmacyclics got nearly a 6% bounce on 8 April after the company and its partner Janssen disclosed that the US FDA granted an additional breakthrough therapy designation for ibrutinib as monotherapy to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in patients with deletion of the short arm of chromosome 17.